Skip to main content
SpringerLink
Log in

Prevalence of potential drug–drug interactions in outpatients on treatment with parenteral antineoplastic drugs

  • Short Research Report
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background As live expectancy and cancer incidence growing, polypharmacy in oncology patients is also increasing, raising the risk of developing potential drug–drug interactions.Objective To assess the prevalence of clinically relevant potential drug–drug interactions among cancer patients who receive parenteral treatment at our outpatient clinic. Method Retrospective observational study which included randomly selected patients who had received parenteral treatment from November 1st 2016 to January 31st 2017. Interactions were checked in 3 databases, and classified as clinically relevant or not and in three categories of severity: contraindicated, consider modification or monitor. Results A total of 273 patients were included; of which seventy three (26.7%) had at least one clinically relevant potential drug–drug interaction. Amongst them, 54 (74%) had at least one classified as monitor treatment, 50 (68.5%) as contraindicated and 26 (35.6%) as consider modification. The number of chronic prescriptions was associated with a higher risk of drug interactions. Conclusion Around one in four patients on treatment with parenteral antineoplastic drugs presented a clinically relevant potential drug–drug interaction. A systematic assessment of drug–drug interactions should be implemented to reduce the risk of clinically relevant drug–drug interactions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386386.

    Article  CAS  Google Scholar 

  2. Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011;12(13):1249–57.

    Article  Google Scholar 

  3. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99(8):592–600.

    Article  Google Scholar 

  4. Girre V, Arkoub H, Puts MT, Vantelon C, Blanchard F, Droz JP, et al. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78(3):220–6.

    Article  CAS  Google Scholar 

  5. Van Leeuwen RW, Swart EL, Boven E, Boom FA, Schuitenmaker MG, Hugtenburg JG. Potential drug interactions in cancer therapy: a prevalence study using an advanced screening method. Ann Oncol. 2011;22(10):2334–411.

    Article  Google Scholar 

  6. Van Leeuwen RW, Jansman FG, van den Bemt PM, de Man F, Piran F, Vincenten I, et al. Drug–drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol. 2015;26(5):992–7.

    Article  Google Scholar 

  7. Popa MA, Wallace KJ, Brunello A, Extermann M, Balducci L. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol. 2014;5(3):307–14.

    Article  Google Scholar 

  8. Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus FV. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36(6):1251–9.

    Article  Google Scholar 

  9. de Palencia Espinosa MÁF, Carrasco MSD, Romero JLA, de la Rubia Nieto A, Miró AE. Potential drug–drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors. Int J Clin Pharm 2015;37(6):1021–7.

    Article  Google Scholar 

  10. Kheshti R, Aalipour M, Namazi S. A comparison of five common drug–drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257–63.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank Mr. Jonathan McFarland for his contribution in the revision of English language of the manuscript.

Author information

Authors and Affiliations

  1. Pharmacy Department, Hospital Universitari Son Espases, Palma de Mallorca, Spain

    M. Castro-Manzanares, F. do Pazo-Oubiña & R. M. Rodríguez-Rincón

Authors
  1. M. Castro-Manzanares
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. do Pazo-Oubiña
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. M. Rodríguez-Rincón
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Castro-Manzanares.

Ethics declarations

Funding

The authors received no specific funding for this work.

Conflicts of interest

The authors have no conflict of interest to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Castro-Manzanares, M., do Pazo-Oubiña, F. & Rodríguez-Rincón, R.M. Prevalence of potential drug–drug interactions in outpatients on treatment with parenteral antineoplastic drugs. Int J Clin Pharm 41, 1429–1433 (2019). https://doi.org/10.1007/s11096-019-00910-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-019-00910-7

Keywords

Search

Navigation